3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
8
Uterine Cervical Neoplasms
5
Melanoma
5
Head and Neck Neoplasms
5
Urinary Bladder Neoplasms
4
Triple Negative Breast Neoplasms
4
Stomach Neoplasms
4
Neoplasms
4
Fallopian Tube Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Prostatic Neoplasms
2
Kidney Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Vulvar Neoplasms
1
Uveal Melanoma
1
Uterine Neoplasms
1
Thyroid Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Interventions
fludarabine phosphate
1
fludarabine
1
cemiplimab
1
aldesleukin
1
Sampling Studies
1
Respiratory Function Tests
1
Prochlorperazine
1
Positron-Emission Tomography
1
Ondansetron
1
O(6)-codeine methyl ether
1
Meperidine
1
Magnetic Resonance Imaging
1
Loperamide
1
Interleukin-2
1
Innovar
1
Indomethacin
1
Hydroxyzine
1
Granisetron
1
Electrocardiography
1
Droperidol
1
Doxylamine
1
Diphenoxylate
1
Diphenhydramine
1
Cyclophosphamide
1
Codeine
1
Cell Count
1
Blood Specimen Collection
1
Biopsy
1
Atropine
1
Acetaminophen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma in Situ
×
cemiplimab
×
Gynecologic
×
Clear all
NCT06022029
2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1
Recruiting
168 enrolled